SCIENCE-FIRST CDMO ENGINEERING FOR GLOBAL MEDICAL BRANDS.
Olympia operates as an evidence-based technology platform: AI toxicology screening, physicochemical feasibility diagnostics, PPQ-grade process discipline, and unconditional 100% IP transfer. We own zero consumer brands, so structural conflict is eliminated by design.
STRUCTURAL ASYMMETRY · MANIFESTO §3
0 own consumer brands. 0 competing SKUs. 0 channel conflict.
OWN CONSUMER BRANDS
0
COMPETING SKUS HELD
0
EXCLUSIVITY CLAUSES VIOLATED, 17 YRS
0
RISK ELIMINATION · CLINICAL IP ARCHITECTURE
WE ENGINEER CLINICALLY DEFENSIBLE SUPPLEMENTS, NOT BROCHURE CLAIMS.
Our first deliverable is control: zero competitive conflict, ISO/IEC 27001 information governance, legal/regulatory supervision, AI toxicology screening, and PPQ-aligned manufacturing discipline. Our second deliverable is enterprise value: proprietary formula architecture, project-specific sourcing, and full IP ownership transferred to your company.
YEARS - ZERO-COMPLAINT DISCIPLINE
QUALITY COMPLAINTS. EVER.
UNCONDITIONAL IP TRANSFER
INFORMATION SECURITY SHIELD
TRUST IS CHEAP. PUBLIC RECORDS ARE NOT.
Our authority is documented in auditable systems: Warsaw Stock Exchange filings naming Olympia alongside Lycotec, Adiuvo Investments, Symrise AG and Carocelle; scale-up of Cambridge spin-off technology; and NCBiR-patronised programmes. Compliance-grade proof, not marketing narrative.
Additional third-party validation includes Forbes coverage, the Rome International Award, and independent media scrutiny. Every core statement is anchored in legal, analytical, and capital-market documentation that any due-diligence team can verify before a call is even booked.
MOST-READ CLINICAL INTELLIGENCE — LIVE RANKING
Major Advances in Rheumatology: 2025–2026 Breakthroughs
Treatments for chronic conditions where the body's own defense system mistakenly attacks itself, like lupus and art…
Clinical Advancements in Brain-Computer Interfaces: Speech, Motor, and Sensory Neuroprosthetics
New brain devices are making a significant difference for people with severe paralysis or blindness. These clever i…
Xenotransplantation Progresses to Formal Clinical Trials: A 2026 Update on Pig-to-Human Organ Transplants
Pig-to-human organ transplants are now moving into formal human studies, most notably for kidney patients needing a…
A FORMULA WITHOUT PHYSICOCHEMICAL VALIDATION IS NOT A PRODUCT.
Many formulations that look viable on paper fail under real transport and storage stress. Without validated stability windows, suspensions crystallize, agglomerate, or separate under thermal gradients.
Fast quote cycles often model assumptions, not production reality. Paid Discovery executes feasibility diagnostics, AI safety screening, and Proof-of-Concept runs to establish a validated technical path before capital is committed.
PAID DISCOVERY — SCIENTIFIC CONTROL GATE
- > ELIMINATES NON-TECHNICAL BRIEFS AND PRICE-ONLY REQUESTS.
- > CONFIRMS SCIENTIFIC SCOPE, REGULATORY PATH, AND EXECUTION CAPACITY.
- > PRODUCES POC DATA, STABILITY DIRECTION, AND MANUFACTURING SPECIFICATION.
- > ESTABLISHES OLYMPIA AS SCIENTIFIC LEAD; ENGAGEMENT IS BY QUALIFICATION.
PILLAR 2 ECONOMICS · LIVE COMPOUND DRIFT
EVERY QUARTER YOU DELAY R&D, THE PROGRAMME COSTS MORE TO START.
We model effective programme cost as base R&D × (1 + 19.2%)^years, where the 19.2% rate combines CPI inflation (7.2%) with the CDMO risk buffer (12.0%) for raw material volatility, regulatory drift, and capacity scarcity. The drift compounds in real time below.
BASELINE R&D · TODAY
0.00%
COST IF YOU START IN 12 MONTHS
+19.20%
+19.2% DRIFT
DRIFT ACCRUED SINCE PAGE LOAD
+0.000000%
@ 19.2% / YR · COMPOUNDED PER SECOND
WE QUALIFY FOR SCIENTIFIC FIT BEFORE COMMERCIAL SCALE.
Paid Discovery is a deductible R&D deposit, not advisory theater. It includes feasibility diagnostics, AI toxicology screening, and Proof-of-Concept production. You receive technical documentation, stability direction, and unconditional 100% IP transfer under a zero-conflict operating model.
INITIATE R&D DUE DILIGENCE